Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures

NCT05475366 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Pancreatic Ductal
Prognosis

Interventions

OTHER: Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC
OTHER: Biomarkers of tumor signatures (translational studies)

Sponsor

Institut Curie